Cannabis stocks have had significant momentum due to positive regulatory changes in the U.S. However, this momentum is likely to be relatively short-lived. These 10 Stocks Could Mint the Next Wave of Millionaires ›

Marijuana's potential move to Schedule III could reshape cannabis economics, putting CRON, VFF and TLRY in focus for 2026 investors.

On Dec. 18, 2025, President Trump signed a pivotal Executive Order directing the Attorney General to expedite the rescheduling of cannabis. By all traditional metrics, this political victory should have sparked a sustained rally.

The cannabis industry continues evolving into a bigger and more regulated global market. Legalization trends are expanding across the United States and international regions. This growth fuels long-term opportunities for marijuana stock investors and those looking to get invested in the industry. Cannabis stocks benefit from increasing consumer demand and acceptance. Medical cannabis adoption supports consistent revenue and defensive market positioning.

President Trump has ordered that marijuana be reclassified as a Schedule III drug. The move doesn't fully legalize marijuana -- yet -- but it may foreshadow changes to come.

The cannabis industry is entering another critical growth phase, positioning 2026 as a potentially pivotal year. Particularly for long-term investors looking to make a profit with marijuana stocks. After years of regulatory uncertainty, capital constraints, and volatile price action, relief is being shown. The legal cannabis market is showing clear signs of structural improvement driven by policy reform, consolidation, and expanding global demand.

In 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. While 2025 seemed to be a transition year, 2026 could mark another pivot point. Specifically, one where improved business operations begin to consistently translate into stronger equity valuations across the sector. Investor sentiment may also shift meaningfully.

Tilray's shares have soared since mid-2025, driven by expectations of cannabis reclassification in the U.S. These expectations have now become a reality, and they will have an impact on pot growers in the country. Despite this progress, significant challenges lie ahead for Tilray.

Trump's executive order to reclassify marijuana from Schedule I to Schedule III recognized the valid medical uses of the drug. The move could impact cannabis companies in several ways, including allowing them to deduct more business expenses.

In the most recent trading session, Tilray Brands, Inc. (TLRY) closed at $10.42, indicating a -6.63% shift from the previous trading day.